{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:20:52Z","timestamp":1794849652512,"version":"4.9.1"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373908"],"award-info":[{"award-number":["82373908"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82404918"],"award-info":[{"award-number":["82404918"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2024M752086"],"award-info":[{"award-number":["2024M752086"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["23ZR1460800"],"award-info":[{"award-number":["23ZR1460800"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Research Program of Chinese Academy of Sciences","award":["ZDBS-ZRKJZ-TLC008"],"award-info":[{"award-number":["ZDBS-ZRKJZ-TLC008"]}]},{"name":"Shanghai Key Technology R&D Program \"Cell and Gene Therapy\" Project","award":["25J22800900"],"award-info":[{"award-number":["25J22800900"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>NK cells hold great promise for cancer immunotherapy owing to their intrinsic capacity to recognize and eliminate malignant cells. Nevertheless, broad clinical deployment is hindered by NK-cell properties like poor expansion and refractoriness to genetic modification, as well as by tumor immune-evasion mechanisms. In this study, we applied base-editing technology to precisely modify signal transduction in primary human NK cells, which achieved a high editing efficiency of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT) gene (&amp;gt;90%) in peripheral blood\u2013derived NK (TIGIT BE-NK) cells. TIGIT editing forced tumor-derived CD155 to engage CD226 and thereby converted an inhibitory signal into an activating one that amplified NK-cell cytotoxicity. TIGIT BE-NK cells specifically targeted cancer cells across multiple tumor types and were validated as safe, with minimal off-target effects. Cryopreserved TIGIT BE-NK cells exhibited similar antitumor activity as fresh TIGIT BE-NK cells, supporting their potential as an \u201coff-the-shelf\u201d therapy. Combining TIGIT BE-NK cells and IL2 further improved antitumor immunity. Together, these results underscore the feasibility of using base editing to modify NK cells and significantly enhance their therapeutic potential for treating patients with cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Modifying a single base within the TIGIT gene in NK cells switches inhibitory signaling to an activating axis that enhances antitumor immunity, supporting base editing of immune cells as an immunotherapeutic strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-25-0733","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:19:11Z","timestamp":1776237551000},"page":"1956-1967","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7978-4420","authenticated-orcid":false,"given":"Cheng","family":"Fang","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00z27jk27","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai University of Traditional Chinese Medicine 1 Department of Immunology and Pathogenic Biology, School of Integrative Medicine, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7779-9437","authenticated-orcid":false,"given":"Guanglei","family":"Li","sequence":"additional","affiliation":[{"name":"2Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Lab of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6921-8823","authenticated-orcid":false,"given":"Min","family":"Han","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00z27jk27","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai University of Traditional Chinese Medicine 3 Department of Thoracic Surgery, Putuo Hospital, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4687-3374","authenticated-orcid":false,"given":"Yiming","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00z27jk27","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai University of Traditional Chinese Medicine 1 Department of Immunology and Pathogenic Biology, School of Integrative Medicine, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3104-0070","authenticated-orcid":false,"given":"Wenxia","family":"Yu","sequence":"additional","affiliation":[{"name":"4WLA Laboratories, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7946-7575","authenticated-orcid":false,"given":"Dan","family":"Hu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00z27jk27","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai University of Traditional Chinese Medicine 5 School of Acupuncture, Moxibustion and Tuina, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4116-4855","authenticated-orcid":false,"given":"Jiaojiao","family":"Luo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00z27jk27","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai University of Traditional Chinese Medicine 1 Department of Immunology and Pathogenic Biology, School of Integrative Medicine, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5402-8557","authenticated-orcid":false,"given":"Lixin","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00z27jk27","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai University of Traditional Chinese Medicine 1 Department of Immunology and Pathogenic Biology, School of Integrative Medicine, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0180-0530","authenticated-orcid":false,"given":"Wenwen","family":"Fan","sequence":"additional","affiliation":[{"name":"6Base Therapeutics, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1803-3834","authenticated-orcid":false,"given":"Liling","family":"Wang","sequence":"additional","affiliation":[{"name":"6Base Therapeutics, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-0271","authenticated-orcid":false,"given":"Tianhong","family":"Xu","sequence":"additional","affiliation":[{"name":"6Base Therapeutics, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8934-1247","authenticated-orcid":false,"given":"Xingxu","family":"Huang","sequence":"additional","affiliation":[{"name":"2Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Lab of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3134-0432","authenticated-orcid":false,"given":"Chao","family":"Yao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00z27jk27","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai University of Traditional Chinese Medicine 1 Department of Immunology and Pathogenic Biology, School of Integrative Medicine, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1551-5221","authenticated-orcid":false,"given":"Shiguo","family":"Zhu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00z27jk27","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai University of Traditional Chinese Medicine 1 Department of Immunology and Pathogenic Biology, School of Integrative Medicine, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026041503190038700_bib1","doi-asserted-by":"crossref","first-page":"886429","DOI":"10.3389\/fimmu.2022.886429","article-title":"Next generation natural killer cells for cancer immunotherapy","volume":"13","author":"Rossi","year":"2022","journal-title":"Front Immunol"},{"key":"2026041503190038700_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2026041503190038700_bib3","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"2026041503190038700_bib4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","article-title":"The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies","volume":"21","author":"Bald","year":"2020","journal-title":"Nat Immunol"},{"key":"2026041503190038700_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/cei.12034","article-title":"Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation","volume":"172","author":"Wang","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"2026041503190038700_bib6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"2026041503190038700_bib7","doi-asserted-by":"crossref","first-page":"17858","DOI":"10.1073\/pnas.0903474106","article-title":"The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity","volume":"106","author":"Stanietsky","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026041503190038700_bib8","doi-asserted-by":"crossref","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026041503190038700_bib9","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3390\/cancers15102712","article-title":"TIGIT expression on activated NK cells correlates with greater anti-tumor activity but promotes functional decline upon lung cancer exposure: implications for adoptive cell therapy and TIGIT-targeted therapies","volume":"15","author":"Hasan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026041503190038700_bib10","doi-asserted-by":"crossref","first-page":"e007502","DOI":"10.1136\/jitc-2023-007502","article-title":"Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies","volume":"11","author":"Hasan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026041503190038700_bib11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.tibtech.2019.03.008","article-title":"CRISPR\/Cas-mediated base editing: technical considerations and practical applications","volume":"37","author":"Molla","year":"2019","journal-title":"Trends Biotechnol"},{"key":"2026041503190038700_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ymthe.2019.11.022","article-title":"Efficient gene silencing by adenine base editor-mediated start codon mutation","volume":"28","author":"Wang","year":"2020","journal-title":"Mol Ther"},{"key":"2026041503190038700_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1126\/science.aav9973","article-title":"Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos","volume":"364","author":"Zuo","year":"2019","journal-title":"Science"},{"key":"2026041503190038700_bib14","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1038\/s41467-020-19690-0","article-title":"A Cas-embedding strategy for minimizing off-target effects of DNA base editors","volume":"11","author":"Liu","year":"2020","journal-title":"Nat Commun"},{"key":"2026041503190038700_bib15","doi-asserted-by":"crossref","first-page":"e20201529","DOI":"10.1084\/jem.20201529","article-title":"A robust platform for expansion and genome editing of primary human natural killer cells","volume":"218","author":"Huang","year":"2021","journal-title":"J Exp Med"},{"key":"2026041503190038700_bib16","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1349-7006.2010.01530.x","article-title":"Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma","volume":"101","author":"Nakai","year":"2010","journal-title":"Cancer Sci"},{"key":"2026041503190038700_bib17","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.aao0505","article-title":"Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity","volume":"359","author":"Ferrari De Andrade","year":"2018","journal-title":"Science"},{"key":"2026041503190038700_bib18","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1084\/jem.188.12.2375","article-title":"Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells","volume":"188","author":"Zamai","year":"1998","journal-title":"J Exp Med"},{"key":"2026041503190038700_bib19","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/cdd.2012.141","article-title":"Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells","volume":"20","author":"Liu","year":"2013","journal-title":"Cell Death Differ"},{"key":"2026041503190038700_bib20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing therapy for osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041503190038700_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"2026041503190038700_bib22","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI123955","article-title":"Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J Clin Invest"},{"key":"2026041503190038700_bib23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jcyt.2016.03.295","article-title":"Off the shelf cellular therapeutics: factors to consider during cryopreservation and storage of human cells for clinical use","volume":"18","author":"Woods","year":"2016","journal-title":"Cytotherapy"},{"key":"2026041503190038700_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-1-0716-0338-3_18","article-title":"CRISPR\/Cas9-based gene engineering of human natural killer cells: protocols for knockout and readouts to evaluate their efficacy","volume":"2121","author":"Lambert","year":"2020","journal-title":"Methods Mol Biol"},{"key":"2026041503190038700_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","article-title":"A genetically engineered primary human natural killer cell platform for cancer immunotherapy","volume":"28","author":"Pomeroy","year":"2020","journal-title":"Mol Ther"},{"key":"2026041503190038700_bib26","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/s41587-022-01377-0","article-title":"Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2026041503190038700_bib27","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"2026041503190038700_bib28","doi-asserted-by":"crossref","first-page":"e005829","DOI":"10.1136\/jitc-2022-005829","article-title":"AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors","volume":"11","author":"Frentzas","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026041503190038700_bib29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"key":"2026041503190038700_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","article-title":"Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials","volume":"22","author":"Chu","year":"2023","journal-title":"Mol Cancer"},{"key":"2026041503190038700_bib31","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells","volume":"67","author":"El-Sherbiny","year":"2007","journal-title":"Cancer Res"},{"key":"2026041503190038700_bib32","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/0008-5472.CAN-06-2264","article-title":"DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells","volume":"67","author":"Carlsten","year":"2007","journal-title":"Cancer Res"},{"key":"2026041503190038700_bib33","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"2026041503190038700_bib34","doi-asserted-by":"crossref","first-page":"100521","DOI":"10.1016\/j.medj.2024.09.010","article-title":"Targeting HLA-E-overexpressing cancers with a NKG2A\/C switch receptor","volume":"6","author":"Saetersmoen","year":"2025","journal-title":"Med"},{"key":"2026041503190038700_bib35","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41467-023-40220-1","article-title":"High-throughput characterization of HLA-E-presented CD94\/NKG2x ligands reveals peptides which modulate NK cell activation","volume":"14","author":"Huisman","year":"2023","journal-title":"Nat Commun"},{"key":"2026041503190038700_bib36","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026041503190038700_bib37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.23.01363","article-title":"SKYSCRAPER-02: tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer","volume":"42","author":"Rudin","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026041503190038700_bib38","volume-title":"Genentech reports interim results for phase III SKYSCRAPER-01 study in PD-L1 high metastatic non-small cell lung cancer","author":"Genentech","year":"2022"},{"key":"2026041503190038700_bib39","volume-title":"Genentech provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer","author":"Genentech","year":"2022"},{"key":"2026041503190038700_bib40","doi-asserted-by":"crossref","first-page":"215830","DOI":"10.1016\/j.canlet.2022.215830","article-title":"CD155 in tumor progression and targeted therapy","volume":"545","author":"Zhan","year":"2022","journal-title":"Cancer Lett"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/8\/1956\/3764837\/can-25-0733.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/8\/1956\/3764837\/can-25-0733.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:19:19Z","timestamp":1776237559000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/8\/1956\/782640\/Base-Editing-of-TIGIT-Reprograms-CD155-Signaling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-0733","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.8542406","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.32708861","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708873","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708840","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708870","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708843","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708855","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708822","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708852","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708831","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708810","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708864","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708813","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708858","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708825","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708834","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708867","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708846","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708819","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708849","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708816","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32708828","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}